Arena Pharmaceuticals, Inc. (ARNA) Stock: Do Analysts Think You Should Sell?

Tuesday, October 12, 2021 01:24 PM | InvestorsObserver Analysts

Mentioned in this article

Arena Pharmaceuticals, Inc. (ARNA) Stock: Do Analysts Think You Should Sell?

InvestorsObserver is giving Arena Pharmaceuticals, Inc. (ARNA) an Analyst Rating Rank of 75, meaning ARNA is ranked higher by analysts than 75% of stocks. The average price target for ARNA is $97.428 and analyst’s rate the stock as a Strong Buy.

Wall Street analysts are rating ARNA a Strong Buy today. Find out what this means to you and get the rest of the rankings on ARNA!

See Full ARNA Report

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported. InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With Arena Pharmaceuticals, Inc. Stock Today?

Arena Pharmaceuticals, Inc. (ARNA) stock has gained 3.21% while the S&P 500 is lower by -0.2% as of 1:17 PM on Tuesday, Oct 12. ARNA has gained $1.94 from the previous closing price of $60.40 on volume of 208,968 shares. Over the past year the S&P 500 has gained 23.15% while ARNA is lower by -26.30%. ARNA lost -$8.17 per share the over the last 12 months. Click Here to get the full Stock Report for Arena Pharmaceuticals, Inc. stock.